News

"We are very pleased to announce the enrolment of the first patient in this important and second indication for our lead product. This is another important milestone for

In preclinical studies, AG-881 was shown to fully penetrate the blood-brain barrier and inhibit IDH1 and IDH2 mutations in cancer models. IDH1 and IDH2 are two metabolic enzymes

According to Fenix Leung, DPhil, GlobalData’s Analyst covering Oncology and Hematology, data from BMS’ Phase III trial, CheckMate-067, which compared the combination of the Opdivo (nivolumab) and Yervoy

They have also announced the addition of 100 snakes to the existing milking line to increase venom production for the upcoming international orders from India and China. "We

The Phase II trial is being conducted under an investigational new drug (IND) application to the US Food and Drug Administration (FDA) and is the first to test

Oxycodone is used in the management of pain, especially in opioid tolerant patients. The company will introduce the product soon and will be amongst the few generic versions

Both the entities will jointly work to further develop the Etubics Platform, which is employed to develop new immunotherapeutic product candidates to treat cancer. As part of the

SMA is characterized by lower motor neuron loss and progressive muscle weakness and is caused by a genetic defect in the SMN1 gene that codes SMN, a protein

Progenics Pharmaceuticals has exclusively licensed development and commercialization rights for its first commercial product, Relistor, to Valeant. Relistor is a peripherally acting mu-opioid receptor antagonist designed to block